Moderna Triples in 90 Days — and Quietly Doesn't Enroll the Cohort

The Quarter the Story Changed Shape

Moderna is not a stock in motion. It is a stock in flight. The tape shows a +218.7% return over the last 90 trading days, with a two-week stretch alone adding 141% and a nine-week run stacking another 84% on top. And yet, after all that, the shares still sit 47.5% below the August 2021 peak of $484.47. That is the whole setup in one line: a company whose market capitalization is back above $100 billion, whose equity has more than tripled in a quarter, and whose owners are still deeply underwater versus the pandemic bubble. Everything in this report is a question about whether the second half of that sentence finally stops mattering.

The mechanism behind the re-rating is unambiguous. In October, the Phase 3 INTerpath-001 trial of intismeran autogene, the individualized neoantigen therapy partnered with Merck, delivered a hazard ratio of 0.58 and a p-value below 0.001 against pembrolizumab alone in resected stage IIB–IV melanoma — a 42% reduction in the risk of recurrence or death, and the first positive Phase 3 for an individualized cancer vaccine. Two-year recurrence-free survival was 82.2% versus 70.0%. That is a company-defining number, not a sector number.

The Commercial Business Showed Up Too

Buried under the oncology fireworks is a genuinely better-than-expected commercial quarter. Third-quarter revenue came in around $1.3 billion with net income of $162 million — a swing of $362 million year over year — and management used it to do something it has not done in years: raise the year materially at the midpoint rather than defend a range. “we are increasing our full year revenue framework to a range of 15% to 25% growth, which exceeds our prior framework of up to 10% growth” — James Mock, Chief Financial Officer · 2026-11-06. Crucially, the CFO framed it as broad-based rather than a shipment-timing artifact: vaccination rates are described as stable in the U.S., and year-to-date international revenue of roughly $900 million is already $200 million ahead of the entire prior year.

The franchise engine is mNEXSPIKE taking share inside the COVID book, and the respiratory portfolio got its fifth approval — mFLUSIVA, the first mRNA influenza vaccine to reach market, plus Canadian approvals for both mFLUSIVA and the combination product. Roughly 44.1 million flu, COVID and RSV shots have gone into arms in U.S. retail and long-term care through late October, a 3% increase year over year. The respiratory vaccine business is no longer the melting ice cube of the 2025 narrative.

The Balance Sheet Became a Weapon

The most under-discussed item on the call was the capital-markets move. “we raised $3 billion for a 0% convertible note” — Stéphane Bancel, Chief Executive Officer · 2026-11-06 — roughly $2.6 billion net after capped calls and fees — landing at a zero coupon with the stock at a multi-year high. That is the single most favorable piece of financial engineering this company has executed since the pandemic. Cash and investments ended at $8.0 billion, and the year-end projection was lifted to $8.1–8.3 billion.

— a reminder that the war chest was partly bought, not purely earned.

At the same time the company kept cutting. R&D fell 27% year over year to $583 million, the full-year R&D framework dropped another $200 million to $2.7 billion, and the adjusted cash cost target was cut to roughly $3.8 billion. Research and development has now fallen 41% from its $1.2 billion peak in 2024Q2. The financial discipline refrain has been on this transcript for six straight quarters, and unlike most corporate refrains, the line items actually corroborate it.

What Management Stopped Saying

Here is where the story gets more interesting than the headline. Two programs were verbally de-risked on this call relative to prior ones, and neither got a press release.

First, renal cell carcinoma. For three consecutive quarters, Stephen Hoge and David Berman framed the fully enrolled, randomized Phase 2 in RCC as designed to preserve registrational optionality. On this call, that language softened into something much more hedged: “at a base case, I would say it can be practice informing... In an upside, if the results are very strong, I think we can consider taking it to FDA, but it will be data dependent” — David Berman, Head of Oncology Development · 2026-11-06. That is a materially different bar than the one set in May, when the framing was that the study “has registrational potential” — Stephen Hoge, President · 2026-05-01. The renal cell readout, expected event-driven around year-end or early next year, is now the single largest binary in the equity — and the company has quietly widened the range of acceptable outcomes.

Second, and more pointedly, norovirus. In July the message was that a third winter season of case accrual was coming: “we know we will need additional cases from a further cohort to strengthen that statistical analysis, and we're working hard on preparing to stand up that part of the study now” — Stephen Hoge, President · 2026-07-31. On this call, the cohort evaporated.

We did not meet the criteria for early success. And we were going forward with a cohort initially. But as we review the program, we think the most appropriate next step is not to go forward with that cohort, but instead consult with regulators.

That is the criteria for early success language recurring — but this time as an epitaph rather than a hurdle. Note the pattern: the norovirus program has now consumed two seasons, missed its interim, and lost its follow-on cohort, and the disclosure came only in response to an analyst who asked directly. The risk of recurrence in the infectious disease pipeline is no longer hypothetical.

The Moat Argument — and the Tape That Agrees

Where management was expansive rather than defensive was on the algorithm. Asked why competitors cannot simply catch up on neoantigen selection, Hoge leaned into the data asset: “that data is a gold mine” — Stephen Hoge, President · 2026-11-06, citing roughly a tenfold increase in patient experience from the Phase 2 to the Phase 3, with another fivefold step coming across the nine other running studies. The supporting MITT analysis — a 49% reduction in recurrence or death and a hazard ratio of 0.51 among patients actually dosed — is the number that matters commercially, because it links the effect to the product rather than to trial mechanics, and it matches the Phase 2 hazard ratio at three and five years.

The market's own thematic tape is already voting on this. durability of response is among the strongest 90-day advancers across the whole immunotherapy cohort, and the broader personalized-medicine complex has been re-rated. Moderna is not riding a wave here so much as it is supplying one of the waves' defining data points. Price to revenue has re-rated to 12.5x, up 260% year over year.

The One Thing to Watch

The bull case now rests on a clean sequencing: intismeran BLA filed this year, approval next year, with Merck carrying the regulatory file and Moderna shipping product at cost plus markup on a 50/50 profit split. Everything else — the convertible, the R&D cuts, the stable vaccination rate — is scaffolding around that event. What makes this quarter genuinely unusual is that management, on the same morning it raised guidance and printed a historic hazard ratio, also quietly retired a pipeline program and softened a registrational claim. That is a company confident enough to take a victory lap and disciplined enough to stop funding its losers in the same breath. Whether the market has priced the second habit as well as it has priced the first is the open question.